← Leaderboards
David G Denardo
Washington University
$14,438,310
Attributed
$22,640,761
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,975,413 · 13
By mechanism
R01$17,052,860 · 7
P50$9,154,604 · 3
U01$1,732,087 · 1
U54$809,608 · 1
R21$226,254 · 1
Top collaborators
- Rebecca L Aft5 shared
- Carl Deselm5 shared
- Vineet Gupta5 shared
- Hyun Kim5 shared
- Julie Kristina Schwarz5 shared
- Mark A Watson5 shared
- Ryan C Fields4 shared
- Li Ding3 shared
Most similar at Washington University
Same institution · by research overlap
- Douglas Robert Spitz$16,909,444
- Mark A Watson$16,564,971
- Rebecca L Aft$2,199,928
- David F Wiemer$887,365
- Carl Deselm$3,462,677
Others in their field
Top investigators on “Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,653,178
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$111,361,061
- Robert H Vonderheide · University Of Pennsylvania$84,159,371
- Sharon A Nachman · Johns Hopkins University$74,725,055
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
Research focus
ImmunotherapyTumorResponseMalignant Neoplasm Of PancreasT-LymphocytePancreatic Ductal AdenocarcinomaInfiltrationImmuneTumor ImmunityTumor MicroenvironmentMyeloid CellsClinical TrialsImmunityMalignant NeoplasmsMouse ModelCheckpoint TherapyResistanceSignal TransductionChemotherapyMyelogenousNeoplasm MetastasisDensityTissuesT Cell Response
Grant awards (56)
Washington University SPORE in Pancreatic Cancer$2,178,396
P50 · FY2025 · CA · contact PI
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer$653,623
R01 · FY2025 · CA
Stomal Senescence Regulator of Tumor Immunity and Progression$634,970
R01 · FY2025 · CA · contact PI
Re-wiring PDAC Tumor Immunity Through Dendritic Cells$473,084
R01 · FY2025 · CA · contact PI
The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity$461,446
U01 · FY2025 · CA · contact PI
Project 1: Employing CD11b-Agonists to Render PDAC Responsive to Immunotherapy$377,428
P50 · FY2025 · CA · contact PI
Research Project Pancreatic Cancer$238,949
U54 · FY2025 · CA · contact PI
Washington University SPORE in Pancreatic Cancer$2,091,214
P50 · FY2024 · CA · contact PI
Stomal Senescence Regulator of Tumor Immunity and Progression$648,846
R01 · FY2024 · CA · contact PI
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer$620,943
R01 · FY2024 · CA
The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity$612,272
U01 · FY2024 · CA · contact PI
Re-wiring PDAC Tumor Immunity Through Dendritic Cells$561,734
R01 · FY2024 · CA · contact PI
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy$422,422
R01 · FY2024 · CA · contact PI
Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity$412,324
R01 · FY2024 · CA · contact PI
Project 1: Employing CD11b-Agonists to Render PDAC Responsive to Immunotherapy$362,331
P50 · FY2024 · CA · contact PI
Research Project Pancreatic Cancer$258,389
U54 · FY2024 · CA · contact PI
Washington University SPORE in Pancreatic Cancer$2,065,042
P50 · FY2023 · CA · contact PI
The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity$658,369
U01 · FY2023 · CA · contact PI
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer$640,551
R01 · FY2023 · CA
Re-wiring PDAC Tumor Immunity Through Dendritic Cells$603,069
R01 · FY2023 · CA · contact PI
Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity$549,598
R01 · FY2023 · CA · contact PI
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy$435,761
R01 · FY2023 · CA · contact PI
Project 1: Employing CD11b-Agonists to Render PDAC Responsive to Immunotherapy$357,273
P50 · FY2023 · CA · contact PI
The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer$347,289
R01 · FY2023 · CA · contact PI
Research Project Pancreatic Cancer$312,270
U54 · FY2023 · CA · contact PI
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer$640,551
R01 · FY2022 · CA
Re-wiring PDAC Tumor Immunity Through Dendritic Cells$603,590
R01 · FY2022 · CA · contact PI
Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity$557,274
R01 · FY2022 · CA · contact PI
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy$435,761
R01 · FY2022 · CA · contact PI
The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer$347,286
R01 · FY2022 · CA · contact PI
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer$629,761
R01 · FY2021 · CA
Re-wiring PDAC Tumor Immunity Through Dendritic Cells$551,987
R01 · FY2021 · CA · contact PI
Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity$549,025
R01 · FY2021 · CA · contact PI
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy$444,655
R01 · FY2021 · CA · contact PI
The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer$354,375
R01 · FY2021 · CA · contact PI
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy$458,317
R01 · FY2020 · CA · contact PI
Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity$453,504
R01 · FY2020 · CA · contact PI
The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer$354,188
R01 · FY2020 · CA · contact PI
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY$348,844
R01 · FY2020 · CA · contact PI
Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy$336,191
P50 · FY2020 · CA · contact PI
The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer$352,688
R01 · FY2019 · CA · contact PI
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY$338,378
R01 · FY2019 · CA · contact PI
Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy$319,955
P50 · FY2019 · CA · contact PI
Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy$371,255
P50 · FY2018 · CA · contact PI
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY$348,844
R01 · FY2018 · CA · contact PI
REPROGRAMMING THE METASTATIC MICROENVIRONMENT OF PANCREATIC CANCER THROUGH CSF1R$316,438
R01 · FY2018 · CA · contact PI
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY$348,844
R01 · FY2017 · CA · contact PI
Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy$338,182
P50 · FY2017 · CA · contact PI
REPROGRAMMING THE METASTATIC MICROENVIRONMENT OF PANCREATIC CANCER THROUGH CSF1R$316,438
R01 · FY2017 · CA · contact PI
Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy$357,337
P50 · FY2016 · CA · contact PI
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY$348,844
R01 · FY2016 · CA · contact PI
REPROGRAMMING THE METASTATIC MICROENVIRONMENT OF PANCREATIC CANCER THROUGH CSF1R$316,438
R01 · FY2016 · CA · contact PI
REPROGRAMMING THE METASTATIC MICROENVIRONMENT OF PANCREATIC CANCER THROUGH CSF1R$316,438
R01 · FY2015 · CA · contact PI
TARGETING CCR2 TO OVERCOME IMMUNOSUPPRESSION AND IMPROVE IMMUNOTHERAPY$102,843
R21 · FY2015 · CA · contact PI
REPROGRAMMING THE METASTATIC MICROENVIRONMENT OF PANCREATIC CANCER THROUGH CSF1R$316,178
R01 · FY2014 · CA · contact PI
TARGETING CCR2 TO OVERCOME IMMUNOSUPPRESSION AND IMPROVE IMMUNOTHERAPY$123,411
R21 · FY2014 · CA · contact PI